Coker, Shodeinde A.
Hurwitz, Herbert I.
Sharma, Sunil
Wang, Ding
Jordaan, Pierre
Zarate, Juan Pablo
Lewis, Lionel D.
Funding for this research was provided by:
GlaxoSmithKline
Article History
Received: 19 April 2019
Accepted: 22 May 2019
First Online: 11 June 2019
Compliance with ethical standards
:
: SAC: Has declared no conflicts of interest regarding the conduct of this clinical trial or drafting the manuscript. HIH: Received research funding from GlaxoSmithKline, paid through Duke University Medical Center at the time of this work and drafting the manuscript. He is currently employed by Genentech/Roche and owns Roche stock. SS: Received research funding from GlaxoSmithKline/Novartis at the time of this work and has served on GlaxoSmithKline and Novartis Advisory Boards. DW: Has declared no conflicts of interest regarding the conduct of this clinical trial or drafting the manuscript. JPZ: Is employed by Novartis. LDL: Received research funding from GlaxoSmithKline/Novartis, paid through Dartmouth College to support the costs of this study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the participating institutional and/or national research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.